Program
Telmisartan
Also written as “telmisartan”, “CKD-828, D097, D337” and “Telmisartan 40 mg”.
Its studies are mostly in Hypertension · Essential Hypertension · Diabetic Nephropathies · Hypercholesterolemia · Hyperlipidemias, led by 15 companies.
Drug pageTelmisartan: every studyMany companies study it; this page follows only the 130 they lead. All 177 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 900 open or running | phase 4since May 2, 2002 | May 2, 2002 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 122 open or running | phase 4since Mar 9, 2023 | May 20, 2010 | none ahead |
| Yuhanits history only | 81 open or running | phase 4since Nov 10, 2016 | May 29, 2014 | none ahead |
| IlDong Pharmaceuticalits history only | 40 open or running | phase 3since Mar 5, 2014 | Mar 5, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 30 open or running | phase 3since Mar 8, 2017 | Mar 9, 2015 | none ahead |
| Daewon Pharmaceuticalits history only | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| George Medicines PTYits history only | 20 open or running | phase 3since Aug 15, 2020 | Aug 15, 2020 | none ahead |
| HK inno.Nits history only | 20 open or running | phase 1since Aug 25, 2021 | Aug 25, 2021 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 1since Mar 4, 2013 | Mar 4, 2013 | none ahead |
| DongKoo Bio & Pharmaits history only | 10 open or running | phase 1since Feb 8, 2018 | Feb 8, 2018 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 3since Dec 2, 2020 | Dec 2, 2020 | none ahead |
| Huons Globalits history only | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Pharmtechnologyits history only | 10 open or running | phase 1since Oct 8, 2018 | Oct 8, 2018 | none ahead |
| Samil Pharmaceuticalits history only | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
| THPharmits history only | 10 open or running | phase 1since Sep 8, 2023 | Sep 8, 2023 | none ahead |
Also a collaborator on its studies: Linical Korea, GlaxoSmithKline and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Aug 12, 2014.
- Aug 15, 2020George Medicines PTY’s first studies: 2 phase 3 studies in HypertensionNew to George Medicines PTYGeorge Medicines PTY · NCT04518306, NCT04518293
- Dec 2, 2020Hanlim Pharm.’s first study: phase 3 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT04659070 · 156 enrolled · Korea, Republic of
- Apr 29, 2021Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT04883658 · 62 enrolled · Korea, Republic of
- Aug 25, 2021HK inno.N’s first study: phase 1 study in HypertensionNew to HK inno.NHK inno.N · NCT05040880 · 46 enrolled · Korea, Republic of
- Jan 4, 2022Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05192356 · 63 enrolled · Korea, Republic of
- Jan 23, 2022Phase 1 study in HypertensionHK inno.N · NCT05223101 · 46 enrolled · Korea, Republic of
- Sep 18, 2022Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05549401 · 32 enrolled · Korea, Republic of
- Feb 20, 2023Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05749861 · 65 enrolled · Korea, Republic of
- Mar 9, 2023Phase 4 study in Essential HypertensionChong Kun Dang Pharmaceutical · NCT05843162 · 116 planned
- Sep 4, 2023Phase 4 study in Essential HypertensionYuhan · NCT06041529 · 198 enrolled · South Korea
- Sep 8, 2023THPharm’s first study: phase 1 study in HypertensionNew to THPharmTHPharm · NCT06063109 · 51 enrolled · South Korea
- Oct 29, 2023Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT06112678 · 63 enrolled · Korea, Republic of
- May 22, 2024Phase 4 study in Diabetic NephropathiesChong Kun Dang Pharmaceutical · NCT06431477 · 98 planned · Korea, Republic of
- Aug 5, 2026Huons Global’s first study: phase 1 study in Drug-drug InteractionsNew to Huons GlobalHuons Global · NCT07784608 · 28 planned · South Korea
Ahead
- Apr 2027Primary completion: phase 1 study in Drug-drug InteractionsHuons Global · NCT07784608
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Valsartanrule | Novartis | phase 4 | 145 |
| Losartanrule | Organon | phase 4 | 58 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
The newest 60 of 130 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07784608Drug-drug Interactions · South Korea | 1 | Not yet recruiting | Huons Global | Apr 2027 | 28 |
| NCT06431477Diabetic Nephropathies · Korea, Republic of | 4 | Recruiting | Chong Kun Dang Pharmaceutical | Oct 31, 2025 | 98 |
| NCT06112678Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Feb 19, 2024 | 63 |
| NCT06063109Hypertension · South Korea | 1 | Completed | THPharm | Nov 9, 2023 | 51 |
| NCT06041529Essential Hypertension · South Korea | 4 | Active, not recruiting | Yuhan | Feb 28, 2026 | 198 |
| NCT05843162Essential Hypertension | 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | Dec 31, 2023 | 116 |
| NCT05749861Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jun 7, 2023 | 65 |
| NCT05549401Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Nov 30, 2022 | 32 |
| NCT05223101Hypertension · Korea, Republic of | 1 | UNKNOWN | HK inno.N | Jul 2022 | 46 |
| NCT05192356Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | May 8, 2022 | 63 |
| NCT05040880Hypertension · Korea, Republic of | 1 | Completed | HK inno.N | Oct 31, 2021 | 46 |
| NCT04883658Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jul 20, 2021 | 62 |
| NCT04659070Hypertension · Korea, Republic of | 3 | UNKNOWN | Hanlim Pharm. | May 19, 2022 | 156 |
| NCT04518306Hypertension · United States, Australia, Nigeria and more | 3 | Completed | George Medicines PTY | Sep 19, 2023 | 755 |
| NCT04518293Hypertension · United States, Australia, Czechia and more | 3 | Completed | George Medicines PTY | Aug 11, 2023 | 1,385 |
| NCT04258865Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Apr 26, 2020 | 30 |
| NCT04158076Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Jan 14, 2021 | 131 |
| NCT03889145Healthy | 1 | Completed | IlDong Pharmaceutical | Feb 19, 2014 | 30 |
| NCT03872232Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Aug 12, 2020 | 180 |
| NCT03705533Bioequivalence · Canada | 1 | Completed | Pharmtechnology | Dec 16, 2018 | 26 |
| NCT03662620Hypertension · Korea, Republic of | 1 | Completed | Yuhan | Dec 8, 2018 | 67 |
| NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Jun 16, 2017 | 134 |
| NCT03550859Renal Insufficiency, Chronic · Korea, Republic of | 4 | UNKNOWN | Yuhan | Dec 2021 | 374 |
| NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Jul 12, 2017 | 32 |
| NCT03438955Hyperlipidemias · Korea, Republic of | 1 | UNKNOWN | DongKoo Bio & Pharma | Jul 31, 2018 | 48 |
| NCT03088254Dyslipidemia With Hypertension · Korea, Republic of | 3 | Completed | Jeil Pharmaceutical | Jul 31, 2017 | 126 |
| NCT02968160Metabolic Syndrome · Korea, Republic of | 4 | Terminated | Yuhan | Feb 2018 | 55 |
| NCT03210532Hypertension · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Sep 2017 | 129 |
| NCT02933658Hypertension | 1 | Completed | Daewon Pharmaceutical | Nov 2015 | 71 |
| NCT02738632Essential Hypertension · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Aug 2016 | 300 |
| NCT02579356Essential Hypertension · Korea, Republic of | 1 | Completed | Samil Pharmaceutical | Aug 2014 | 48 |
| NCT02387619Hypertension · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Mar 2015 | 41 |
| NCT02276391Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2008 | 64 |
| NCT02269176Hypertension | 3 | Completed | Boehringer Ingelheim | Jan 2001 | 330 |
| NCT02263989Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2007 | 30 |
| NCT02262858Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2005 | 68 |
| NCT02262793Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2004 | 24 |
| NCT02262780Healthy | 1 | Completed | Boehringer Ingelheim | Feb 15, 2004 | 20 |
| NCT02262650Healthy | 1 | Completed | Boehringer Ingelheim | May 2004 | 24 |
| NCT02262624Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2005 | 36 |
| NCT02262598Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2004 | 30 |
| NCT02262585Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2002 | 30 |
| NCT02262572Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2003 | 24 |
| NCT02262559Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2002 | 30 |
| NCT02261129Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2008 | 64 |
| NCT02261116Healthy | 4 | Completed | Boehringer Ingelheim | Aug 2002 | 24 |
| NCT02261064Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2009 | 32 |
| NCT02260089Hypertension | 4 | Completed | Boehringer Ingelheim | Jul 2002 | 134 |
| NCT02259829Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2007 | 84 |
| NCT02259816Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2006 | 38 |
| NCT02259803Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2007 | 30 |
| NCT02259790Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2007 | 30 |
| NCT02242812Hypertension | 4 | Terminated | Boehringer Ingelheim | Oct 2004 | 24 |
| NCT02242370Hypertension | 4 | Completed | Boehringer Ingelheim | Nov 2000 | 3,045 |
| NCT02242344Hypertension | 2 | Completed | Boehringer Ingelheim | Sep 2007 | 77 |
| NCT02242318Hypertension | 4 | Completed | Boehringer Ingelheim | Sep 2002 | 440 |
| NCT02233218Healthy Male Volunteer · Korea, Republic of | 1 | Completed | Yuhan | Oct 2014 | 60 |
| NCT02218684Healthy | 1 | Completed | Boehringer Ingelheim | Nov 1998 | 27 |
| NCT02215005Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2007 | 42 |
| NCT02214992Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2007 | 84 |
How it is read
Names in the registry
- “Telmisartan”, 38 entries
- “telmisartan”, 7 entries
- “CKD-828, D097, D337”, 6 entries
- “Telmisartan 40 mg”, 6 entries
- “Low dose of telmisartan”, 4 entries
Conditions, from the studies’ own filings
- Hypertension, 77 studies
- Essential Hypertension, 6 studies
- Diabetic Nephropathies, 3 studies
- Hypercholesterolemia, 2 studies
- Hyperlipidemias, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.